Podcast Cruzamento
O Podcast onde a Tecnologia, Saúde e Sustentabilidade se cruzam.
info_outline
100 Episódios de Podcast Cruzamento: E Agora? [PT]
03/04/2025
100 Episódios de Podcast Cruzamento: E Agora? [PT]
Neste episódio do Podcast CRUZAMENTO, e celebram quatro anos de aprendizagem e evolução. Olham para o futuro, onde o formato será mais reflexivo e menos frequente, mas sempre a explorar tendências na tecnologia e saúde, incluindo a revolução no modelo de negócio da indústria farmacêutica, o papel da IA na saúde e a necessidade de uma estratégia a longo prazo. Discutem ainda a importância do talento em Portugal e convidam os ouvintes a sugerirem temas. O podcast evolui, mas mantém-se um espaço de inovação e cruzamento de ideias! Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/35514270
info_outline
99: Podcast Cruzamento: Como Criar um Podcast de Sucesso [PT]
02/18/2025
99: Podcast Cruzamento: Como Criar um Podcast de Sucesso [PT]
Neste episódio do Podcast CRUZAMENTO, e partilham a jornada de quatro anos a criar um podcast sobre tecnologia e saúde 🎙️. Discutem os desafios iniciais, a escolha do nome, a seleção de convidados e o equilíbrio entre profundidade e comunicação clara. Destacam a importância da qualidade e consistência, o impacto inesperado do podcast na comunidade e a evolução para um bootcamp. Revelam ainda bastidores como a preparação dos episódios, a independência editorial e as conversas informais que ficaram offline, mas que foram transformadoras 🚀. Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/35302240
info_outline
98: Podcast Cruzamento: O Ponto de Partida, Onde as Ideias se Cruzaram [PT]
12/17/2024
98: Podcast Cruzamento: O Ponto de Partida, Onde as Ideias se Cruzaram [PT]
Neste episódio do Podcast CRUZAMENTO, e conversam sobre as origens do projeto, partilhando as motivações, os desafios iniciais e os momentos marcantes que deram vida ao podcast. Uma reflexão sobre como as ideias se alinharam e evoluíram para criar este espaço único de diálogo sobre transformação digital, sustentabilidade e saúde. Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/34456835
info_outline
97: Luís Valente: Startup CEOs - Passion Over Glamour? [EN]
12/03/2024
97: Luís Valente: Startup CEOs - Passion Over Glamour? [EN]
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with , CEO of iLOF, a deep-tech health startup, who shared insights on revolutionising personalised medicine. iLOF leverages Optomics—an innovative combination of optical data and AI—to overcome challenges in clinical trials, such as invasive procedures and recruitment inefficiencies. Luis highlights the startup’s impactful partnership in an ambitious Alzheimer’s trial and reflects on the demanding, often misunderstood role of a startup CEO. He offers advice for transitioning from corporates to startups, emphasising stage-appropriate involvement and culture alignment. Success hinges on hiring motivated people, fostering purpose, and prioritising high-performing teams over micromanaging the unmotivated. 🚀 , CEO & Co-Founder @ iLoF Business manager, strategist, and entrepreneur with a drive for using innovative and creative strategies to solve complex problems. Forbes 30 under 30 for Science and Healthcare, with a background in Computer Science, I have spent several years focusing on innovation and improving strategies in companies from Tech to Healthcare. My passion for entrepreneurship led me to create my first business at 18, founding and operating several ventures specializing in optimized demand prediction, lean operations, and design for growth. A deep belief in the power of Technology as the core driver for democratizing Personalized Medicine had me co-founding iLoF: a fast-growing deep tech company using AI to build a cloud-based library of disease biomarkers and biological profiles. Currently on a mission to accelerate adequate treatments for millions of patients living with complex, heterogeneous diseases around the globe. Other relevant references | Outras referências relevantes: Contacts | Contactos: Episode edited by
/episode/index/show/cruzamentopodcast/id/34195445
info_outline
96: Hugo Marques: Histórias de Transformação Digital na Saúde [PT]
11/19/2024
96: Hugo Marques: Histórias de Transformação Digital na Saúde [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com , diretor da Siemens Healthineers em Portugal, partilha a sua paixão por inovação e tecnologia no setor de saúde, abordando projetos inspiradores de transformação digital. Desde a criação do Digital Patient Twin, uma réplica virtual do paciente que permite tratamentos personalizados, até ao projeto de interoperabilidade nos Açores, o Hugo destaca o impacto da digitalização e IA no acesso global à saúde. Conversámos também sobre as parcerias em Cabo Verde, onde a Siemens Healthineers moderniza hospitais, e o papel de Portugal como centro de excelência em tecnologia médica, fortalecendo o setor Medtech. é reconhecido como uma liderança influente no sector da saúde, dedicando-se a potenciar a humanização e a eficiência dos cuidados de saúde por meio da inovação digital. Atualmente lidera a área de Digital & Automação, na Siemens Healthineers Portugal, onde impulsiona a integração de novas competências tecnológicas e a humanização no coração da inovação. Com uma trajetória de quase duas décadas na vanguarda da gestão e implementação de soluções digitais em saúde e suporte à decisão clínica (AI), suportada pela paixão no uso da tecnologia médica para melhorar a qualidade de vida da população. É um apaixonado por desporto e equipas de alto impacto, e tem como missão transferir estes valores para área da saúde, garantindo o alinhamento e um propósito com uma visão centrada no paciente, que é simultaneamente empática e inovadora. Citação: A verdadeira revolução na saúde surge quando integramos a racionalidade e sensibilidade humana com a precisão da inteligência artificial, criando realidades que não só entendem as nossas necessidades, mas antecipam-nas. Contacts | Contactos: Episódio editado por
/episode/index/show/cruzamentopodcast/id/33954232
info_outline
95: Podcast Cruzamento: Indústria Farmacêutica - Impactos e Desafios [PT]
11/05/2024
95: Podcast Cruzamento: Indústria Farmacêutica - Impactos e Desafios [PT]
Neste episódio do Podcast CRUZAMENTO, , e conversam sobre como a indústria farmacêutica é fundamental na saúde global, promovendo avanços que aumentam a esperança média de vida. É um setor de grande impacto, mas também arriscado e demorado, com fármacos que levam até 15 anos (e muitos milhares de milhões de euros) em investimentos até chegar ao mercado, sem garantia de lucro. A pandemia COVID-19 exemplificou o poder da colaboração entre empresas e reguladores, reduzindo o tempo de espera. Desafios incluem o equilíbrio entre inovação e regulação e o acesso desigual à saúde, especialmente em países em desenvolvimento, onde novos modelos de negócio sustentáveis estão a ganhar terreno. Contacts | Contactos: Episódio editado por
/episode/index/show/cruzamentopodcast/id/33642432
info_outline
94: Podcast Cruzamento: Inovação Tecnológica Centrada no Paciente [PT]
10/21/2024
94: Podcast Cruzamento: Inovação Tecnológica Centrada no Paciente [PT]
Neste episódio do Podcast CRUZAMENTO, , e conversam sobre o impacto da tecnologia na saúde e a importância da literacia dos pacientes. A crescente acessibilidade a informações médicas online, como através do “Dr. Google” e ChatGPT, cria desafios e oportunidades. Os pacientes devem ser mais capacitados e preparados para consultas, sem substituir os profissionais de saúde, promovendo uma colaboração saudável. Exemplos de inovação, como aplicações médicas específicas em países em desenvolvimento, destacam-se. Finalmente, é essencial que tecnologia e educação avancem lado a lado para facilitar o acesso universal e melhorar a saúde global. Contacts | Contactos: Episódio editado por
/episode/index/show/cruzamentopodcast/id/33514902
info_outline
93: Marco Vidal: Investimento, Futuro Tecnológico e Startups Globais [PT]
10/07/2024
93: Marco Vidal: Investimento, Futuro Tecnológico e Startups Globais [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com sobre inovação tecnológica e o impacto do fundo Berkeley Skydeck, que investe em startups disruptivas nas áreas de inteligência artificial, biotecnologia e saúde. Marco destaca exemplos que utiliza IA para diagnósticos médicos, e o uso de terapia genética CRISPR. Aborda também alguns desafios para startups em Portugal, como a falta de massa crítica, e como empresas como a Nimble, co-fundada por Marco, ajudam a integrar inovações globais no país. O papel das parcerias internacionais é fundamental para o crescimento deste ecossistema. é Partner na Nimble, investidor e Advisor no fundo Berkeley Skydeck, combinando a sua paixão por tecnologias exponenciais e inovação com mais de 12 anos de experiência na Nimble. Como fundador, contribuiu para que a empresa se destacasse nas áreas de Data, Analytics e Inteligência Artificial. Marco partilha também o seu conhecimento como docente na Católica Lisbon School of Business and Economics, onde leciona sobre IA num dos programas de executivos. Ao longo da sua carreira, foi Vice-Presidente de Business Analytics na BOND e co-fundador da AGILLE SA, onde liderou projetos estratégicos em Intelligence. Na sua formação académica, com passagens por instituições de renome como Harvard, IMD e Singularity University, especializou-se em tecnologias exponenciais, IA e inovação. Sempre atento às tendências, Marco colabora ativamente com startups de todo o mundo que se distinguem pela inovação. Other relevant references | Outras referências relevantes: Contacts | Contactos: Episódio editado por
/episode/index/show/cruzamentopodcast/id/33298222
info_outline
92: Pedro Garcia da Silva: Inovação em Saúde [PT]
09/23/2024
92: Pedro Garcia da Silva: Inovação em Saúde [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha estiveram com , no Google Cloud Day Lisbon 2024. Nesta conversa o Pedro Garcia da Silva, diretor de desenvolvimento da Fundação Champalimaud, destacou a missão da instituição: avançar em investigação biomédica e oncologia, criando um ambiente fértil para inovações arriscadas. Exemplos incluem sistemas para personalizar tratamentos de cancro e na aposta que a Fundação faz em radioterapia inovadora e cuidados de saúde domiciliários. O Pedro sublinhou também a importância do talento português e da missão social da Fundação, garantindo o melhor tratamento possível aos seus pacientes. is a neuroscientist, turned engineer, currently serving as a R&D Coordinator and advisor to the Champalimaud Foundation board. Pedro often describes his job description as being ‘the oil’, since his talents are often recruited to facilitate the development and implementation of new technologies at the Champalimaud Foundation, both in fundamental research and clinical support. From neurons to drones and lasers to lancets, Pedro is a technology optimist that is constantly striving to create a virtuous cycle between clinicians and researches. Pedro is a native of Lisbon, having lived most of his adult life in the USA, where he got his bachelor’s in Biology, and a PhD in Neuroscience between the Champalimaud-ITQB and Cold Spring Harbor Laboratory. He is 40 years old, married and has a daughter. Other relevant references | Outras referências relevantes: Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/33144887
info_outline
91: Cristina Campos: Liderança com Propósito [PT]
09/09/2024
91: Cristina Campos: Liderança com Propósito [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com que partilhou as suas experiências sobre o que significa ser uma líder numa grande multinacional em Portugal, liderando centenas de pessoas e enfrentando mudanças de carreira significativas. Discutimos também a importância de viver com propósito e o conceito de uma carreira em portfólio. Além disso, a Cristina ofereceu as suas perspectivas sobre o ecossistema de saúde e os líderes do futuro. é sócia e gestora de um grupo familiar de farmácias. Co-fundadora e presidente da Assembleia Geral de uma associação privada sem fins lucrativos – a TOP Health – que tem como objeto impulsionar, promover, reconhecer e galvanizar o talento em saúde, estimulando uma cultura de excelência e de colaboração entre os diferentes interlocutores do sector, com o propósito de criação de mais valor para os profissionais de saúde e para os resultados em saúde da população. Membro da Direção da UNA (United Nations Association) Portugal e do Supervisory Board do Alumni da Nova SBE e de alguns Conselhos Consultivos. Investidora e mentora. Anteriormente, esteve 18 anos (2004–2022) na Novartis, onde desempenhou diversas funções em Portugal entre as quais a de Presidente do Grupo Novartis durante 9 anos e Diretora Geral da Novartis Farma durante 8 anos (desde 2012). Desde 2021 foi membro do Board da Novartis Global Health e do Novartis ESG Council. Nos primeiros anos da sua carreira trabalhou na Merck Sharp & Dohme e na Procter & Gamble. Nas três multinacionais por onde passou desempenhou funções diversas de gestão e liderança fundamentalmente nas áreas comerciais e de marketing. Foi Vice Presidente da Apifarma - Associação Portuguesa da Indústria Farmacêutica - entre 2015 e 2021 e Presidente do Board do Alumni Club do The Lisbon MBA (Católica|Nova|MIT) entre 2018 e 2021. É licenciada em Ciências Farmacêuticas pela Faculdade de Farmácia da Universidade de Lisboa e fez um MBA na Católica|Nova School of Business. É mãe do André (22), Mateus (20) e Joana (18). Contacts | Contactos: Episódio editado por
/episode/index/show/cruzamentopodcast/id/32432802
info_outline
90: António Lopes: Inteligência Artificial, da Teoria à Prática na Saúde [PT]
08/26/2024
90: António Lopes: Inteligência Artificial, da Teoria à Prática na Saúde [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com sobre como a Inteligência Artificial (IA) e Machine Learning (ML) estão a transformar a saúde. Por exemplo, como a IA simula a inteligência humana em máquinas, enquanto ML ensina essas máquinas a aprender com dados. Exploram aplicações práticas, como a detecção precoce de doenças, tais como, modelos do MIT e da Harvard Medical School conseguem prever cancro da mama e pâncreas anos antes do diagnóstico tradicional. Falam também sobre o uso da IA na personalização de tratamentos e na aceleração do desenvolvimento de medicamentos. Por fim, abordam os desafios éticos e técnicos dos países e organizações, como a transparência dos algoritmos e a importância do pensamento crítico na análise dos resultados. é Doutorado em Ciências e Tecnologias da Informação - ramo de Inteligência Artificial (2011, Iscte) e é Investigador de Inteligência Artificial Aplicada no pólo de investigação do Iscte do Instituto de Telecomunicações. Lecionou diversas cadeiras de programação e sistemas de informação no Departamento de Ciências e Tecnologias de Informação do Iscte ocasionalmente desde 2001 e com mais regularidade entre 2008 e 2013. É atualmente o coordenador do Gabinete de Desenvolvimento de Sistemas de Informação do ISCTE. Other relevant references | Outras referências relevantes: Contacts | Contactos: Episódio editado por
/episode/index/show/cruzamentopodcast/id/32431992
info_outline
89: Rui Soares e Filipe Freitas Pinto: Transformação Digital na Saúde: Inovação e Desafios [PT]
08/12/2024
89: Rui Soares e Filipe Freitas Pinto: Transformação Digital na Saúde: Inovação e Desafios [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com e sobre o ecossistema da tecnologia de saúde e a transformação digital. Filipe destaca a missão da Knokcare na transformação digital da medicina e a importância de personalizar soluções digitais para atender às necessidades dos pacientes. Rui fala sobre a AgentifAI e a implementação de assistentes digitais inteligentes que trazem empatia e melhoram a interação com pacientes. Exemplos concretos incluem a utilização de IA para automatizar processos e melhorar a experiência do paciente, evidenciando que, embora o foco deva ser no futuro, é essencial resolver os desafios atuais. 56 anos, casado há 25 anos, com 2 filhos (já adultos 😀) , 1 cão, economista de formação e com mais de 25 anos de experiência no setor financeiro, onde desempenhei funções de responsabilidade pela rede comercial, área de marketing, recursos humanos, Banca e Transformação Digital. Desde sempre apaixonado pela área de tecnologia e de como a mesma é um enabler da transformação de negócio das empresas, aceitei o desafio há 1 ano e meio de assumir a responsabilidade Comercial e de Marketing da AgentifAI - empresa portuguesa pioneira e inovadora na área de Conversational AI. é médico psiquiatra com especialização em medicina farmacêutica e ocupa o cargo de Chief Medical Officer na Knok, empresa líder em telemedicina em Portugal. É um fervoroso impulsionador da adopção de novas tecnologias em cenários reais de saúde, com foco na aplicação prática de Machine Learning e LLMs. Como Google’s Medical AI Ambassador, está na vanguarda das aplicações de AI na medicina. É também docente do Departamento Medicina da Comunidade, Informação e Decisão em Saúde (MEDCIDS) da Faculdade de Medicina da Universidade do Porto. Other relevant references | Outras referências relevantes: Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/32430107
info_outline
88: Sofia Marta e Luís João: IA, Inclusão e Inovação Tecnológica na Saúde [PT]
07/29/2024
88: Sofia Marta e Luís João: IA, Inclusão e Inovação Tecnológica na Saúde [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com e sobre o papel transformador da Google Cloud na aceleração da transformação digital em diversas indústrias, com especial foco na saúde, utilizando inteligência artificial para melhorar diagnósticos e tratamentos. Falaram sobre a importância da tecnologia cloud para as startups; e destacaram-se iniciativas de diversidade e inclusão no sector tecnológico. Concluíram com um olhar sobre as tendências emergentes na área da saúde, especialmente a inteligência artificial generativa, e a sua capacidade de trazer empatia e eficiência aos cuidados médicos. é Country Manager da Google Cloud em Portugal, sendo responsável pela liderança do negócio e crescimento no mercado. A Sofia tem mais de 20 anos de experiência nas áreas da consultoria e de tecnologia acumulados em diversas empresas. Iniciou a sua carreira na Accenture trabalhando em diversas áreas relacionadas com a modernização do setor público, empresa onde regressou uns anos mais tarde como Vice-Presidente com a responsabilidade de reactivar a prática de Saúde e Administração Pública em Portugal. Desempenhou entretanto funções na Glintt, uma empresa portuguesa da área da saúde, como responsável pelo negócio nacional e internacional de smart processes, bem como na Microsoft Portugal. A Sofia é licenciada em Matemática Científica pela Universidade de Lisboa e conta também com uma Pós-Gradução em eBusiness do ISEG. Tem 46 anos, é casada e tem duas filhas. is a senior sales executive with an entrepreneurial spirit and a contagious passion for technology. He is a Status Quo challenger by nature. A Learn-it-all (not a Know-it-all). Simplifier. Trying to inspire everyone through technical leadership. Customer obsessed (listening is good, innovating on customer behalf is great). Luís João is fascinated by people’s potential and growth. Proud mentor and advisor. Results oriented with proven track record and awarded several times. Always a team player (internal and with partners) to compete and win. He speaks on national and international conferences. Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/32316167
info_outline
87: Hugo Barbosa: Global Launches and Business Models in Pharma [EN]
07/15/2024
87: Hugo Barbosa: Global Launches and Business Models in Pharma [EN]
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talk with who take us on a compelling journey from his beginnings in a small northern Portuguese town to a distinguished career spanning multiple countries. Hugo’s insightful discussion delves into the clinical trials cycle, the evolution of drug development, and the transformative power of modern medical science. He talks about the challenges and innovations in pharmaceutical marketing, the critical role of global product teams (GPT), and the strategies for making lifesaving drugs accessible worldwide. Raised in a small town in northern Portugal in the post-April Revolution fervor for democracy and challenging economic times, 's roots are deeply founded in resilience and hope. With over 25 years in the pharmaceutical industry, including a decade in various international roles, Hugo has cultivated a rich professional journey. His career has taken him across seven cities in three different countries, where he has encountered remarkable individuals, immersed himself in diverse cultures, and broadened his understanding of the world. Hugo believes he can leave the world a little better than he found it. And he tries to do so through the people he interacts with every day, whether at work, at home or at leisure! Contacts | Contactos: Episode edited by
/episode/index/show/cruzamentopodcast/id/32120707
info_outline
86: Nuno Prego Ramos: Biotech Oncology Innovations [EN]
07/01/2024
86: Nuno Prego Ramos: Biotech Oncology Innovations [EN]
In today’s episode of CRUZAMENTO Podcast, hosts André Correia and Daniel Guedelha sit down with biotech entrepreneur to explore the intersection of technology and healthcare. Nuno shares insights into his groundbreaking work at Cellmabs, a biotech company focusing on cancer-specific antigens, and its landmark deal with BioNTech. He also introduces Valvian, his new venture targeting age-related diseases and hard-to-treat tumours using AI-driven immunotherapies. Nuno discusses the importance of developing proprietary AI models for healthcare, the challenges of data privacy, and the necessity of curating high-quality data. The conversation highlights Portugal’s potential as a biotech hub, emphasising the need for talent retention, ecosystem development, and international collaboration to drive innovation in the life sciences sector. is the founder and CEO of , a Portuguese biotech company launched in January 2024 and announced at the East Coast Grand Investors Conference by Johnson & Johnson Innovation. With a law degree from the University of Lisbon further pursuing a Masters and Ph.D. in Biochemistry and immuno-oncology from Lisbon University, Nuno transitioned from a career in pharmaceuticals to focus on biotechnology. He founded CellmAbs in 2019, developing promising cancer therapies based on humanized monoclonal antibodies. Following the sale of these molecules to BioNTech in January 2024, he established Valvian, aiming to revolutionize cancer and longevity therapies through AI-driven research and to position Portugal as a global biotech leader. Contacts | Contactos: Episode edited by
/episode/index/show/cruzamentopodcast/id/31939837
info_outline
85: Pedro Correa de Sampaio: Biotech e Empreendedorismo Científico em Oncologia [PT]
06/17/2024
85: Pedro Correa de Sampaio: Biotech e Empreendedorismo Científico em Oncologia [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com , a viver no Reino Unido, que transformou a sua paixão pela investigação em oncologia numa promissora startup biotecnológica, a Neobe Therapeutics. O Pedro partilha como foi a transição do mundo académico para a fundação da Neobe, uma empresa inovadora que utiliza engenharia genética para desenvolver terapias revolucionárias contra o cancro. Explica a analogia do “Cavalo de Tróia” para atacar tumores e discute os desafios de financiamento de startups no Reino Unido, além dos potenciais obstáculos e oportunidades em Portugal. Reflete sobre o talento e a ética de trabalho dos cientistas portugueses no exterior e a necessidade de mudança de mentalidade nas universidades e no sector empresarial português para fomentar o empreendedorismo científico. Uma conversa rica em insights sobre a interseção entre saúde, inovação e transformação digital. received his PhD in Oncology from the University of Cambridge, where he first developed his interest in understanding and targeting different components of the tumour microenvironment (TME). He initially focused on the study of angiogenesis – the formation of new blood vessels in cancer, after which he moved to the MD Anderson Cancer Center in Houston, Texas. There, he developed methods to study the spatial interactions between TME components, and observed how they could prevent the effective infiltration of immune cells. That led him to move back to London and found Neobe, an early stage startup aimed at genetically engineering bacteria to disrupt these barriers and enable immunotherapy efficacy in solid tumours. Other relevant references | Outras referências relevantes: Contacts | Contactos: Episódio editado por
/episode/index/show/cruzamentopodcast/id/31761401
info_outline
84: Francisco Aguiar: Navigating Healthcare's Digital Evolution [EN]
06/03/2024
84: Francisco Aguiar: Navigating Healthcare's Digital Evolution [EN]
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha dive into the dynamic world of healthcare’s digital transformation with . From data privacy to precision medicine and wearable health tech, discover how organisations are reshaping patient care and driving innovation. Explore key trends and insights shaping the future of healthcare in this enlightening conversation. is a passionate project and people manager with over 10 years of experience in the life sciences industry. He leverages his data and analytics background to collaborate with key stakeholders and deliver impactful solutions that benefit both our customers and patients. Fostering career and leadership development within his team is a core value for Francisco. He believes in creating an environment where everyone can thrive and contribute their best work. Other relevant references | Outras referências relevantes: Contacts | Contactos: Episode edited por
/episode/index/show/cruzamentopodcast/id/31123673
info_outline
83: Maria Manso: Healthcare with Autonomous Consultations [EN]
05/20/2024
83: Maria Manso: Healthcare with Autonomous Consultations [EN]
In this episode of Cruzamento Podcast, hosts André Correia and Daniel Guedelha dive into the intersection of technology and healthcare with special guest , CEO and co-founder of Tucuvi. Maria shares her journey from biomedical engineering to founding Tucuvi, a company dedicated to addressing healthcare capacity challenges using innovative technology. This platform enables autonomous phone consultations, leveraging empathetic conversational AI to engage patients and streamline healthcare delivery. Maria discusses Tucuvi’s impact on patient care, collaboration with healthcare providers and pharmaceutical companies, and expansion into new markets. She highlights the importance of empathy in technology-driven healthcare solutions and invites listeners to connect with Tucuvi on LinkedIn for more information. This engaging conversation offers insights into the future of healthcare innovation and the role of startups in transforming patient-centred care. is the Co-Founder and CEO of Tucuvi, a leading company in Conversational Artificial Intelligence in healthcare. Tucuvi works side by side with healthcare systems to help deliver quality care in the most efficient way possible to millions of patients. In 2024, she has been recognized as the Most Promising European Woman Innovator by the European Innovation Council. Other relevant references | Outras referências relevantes: Contacts | Contactos: Episode edited by
/episode/index/show/cruzamentopodcast/id/31119413
info_outline
82: Tiago Magalhães: Unveiling the Genomic Frontier [EN]
05/06/2024
82: Tiago Magalhães: Unveiling the Genomic Frontier [EN]
In this episode of the CRUZAMENTO Podcast, hosts André Correia and Daniel Guedelha dive deep into the world of gene sequencing, rare diseases, and the future of healthcare with their guest, . Tiago, a biologist turned bioinformatician, sheds light on the pivotal role of gene sequencing in modern healthcare and its potential to revolutionise patient care. From deciphering the intricacies of raw genomic data to the challenges and opportunities presented by initiatives like the Emirati Genome Program, Tiago provides valuable insights into the intersection of technology and healthcare. The conversation touches upon the high prevalence of rare diseases in the UAE, the impact of genomic data on drug discovery, and the evolving landscape of personalised medicine. Tiago also shares his thoughts on the future of genomics and the vital role of patient advocacy in shaping healthcare outcomes. Throughout the discussion, Tiago’s expertise and passion for the subject shine, making complex topics accessible and engaging for listeners. Who is Tiago Magalhães? My name is and I believe in the power of science and knowledge to make the world a better place. I have a Ph.D in genomics and an EMBA in management of research infrastructures. I am currently the Director of Bioinformatics at G42 Healthcare. G42Healthcare is a leading genomics organization, and currently has the largest cohort of long reads in the world. Before my current position, I was VP for Bioinformatics at Genomics Medicine Ireland and before that I was Executive Director at CCMAR, Portugal, a research organization for Marine sciences. I trained as a genomics scientist studying autism, diabetes, bowel cancer, and ancestry analysis. I have a very strong background in biology, namely in animal models, genetic screens, cell biology, microscopy and molecular biology. Words that describe my daily work: very large scale bioinformatics omics work (MGI, Illumina and ONT), analytics, computational biology, drug discovery, human resources supervision, business strategic thinking, and stakeholders management. Another facet of my CV is entrepreneurship, technology transfer and innovation, as I believe that science only makes sense when applied to solve societal challenges. I was the founder and CEO of a personalized medicine start-up, advised several genomics start-ups, and VCs on the genomics space. I am currently an expert for the H2020 European Union programs, and a reviewer for genomics journals. I have worked/studied in Portugal, Germany, US, Canada, East-Timor, Ireland, Brasil and the UAE. Other relevant references | Outras referências relevantes: Contacts | Contactos: Episode edited by
/episode/index/show/cruzamentopodcast/id/31114828
info_outline
81: EDU: Filipe Costa: Navigating Value-Based Healthcare - A Deep Dive [EN]
04/22/2024
81: EDU: Filipe Costa: Navigating Value-Based Healthcare - A Deep Dive [EN]
In this engaging episode of the new segment Cruzamento Education, hosts André Correia e Daniel Guedelha delve into the world of value-based healthcare with special guest . They explore the fundamental concepts of value-based healthcare, discussing its importance in delivering meaningful outcomes for patients while optimising costs. Felipe provides insights into the key topics of patient-reported outcome measurements, technology integration, financial incentives alignment, and the role of data interoperability in supporting value-based healthcare initiatives. The conversation highlights Portugal’s potential to lead the way in implementing value-based healthcare practices and emphasises the importance of transparency, evidence-based decision-making, and collaboration across the healthcare ecosystem. ’s profile: Professor in Management & VBHC at Nova SBE Exec. Education Researcher in Nova Healthcare Economics & Management Knowledge Centre- Coordinated by Prof Pedro Pita Barros Executive Coordinator of the Pos Graduation of Healthcare Management NOVA SBE Executive Education Past Director of VBHC in Luz Saúde Group Post Graduated in Harvard Business School- Value Based Healthcare MBA and a master in management Areas of interest and research: value-based health, health management, organizatioal theory, operations management, outcomes, cost analysis, payment models and process improvement. Led several national and international management projects in VBHC Distinguished Merit Award the International Federation of Hospitals 2019 in Patient Cantered Care with the Value project Health care based. Best VBHC Group in Portugal price by Accenture, Jansen, APAH, J. Negocios Several publications and International presentations about VBHC Contacts | Contactos: Episode edited by
/episode/index/show/cruzamentopodcast/id/30918718
info_outline
80: Dan Lewi: Rare Disease Advocacy - Trust and Transparency in Action [EN]
04/08/2024
80: Dan Lewi: Rare Disease Advocacy - Trust and Transparency in Action [EN]
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with , co-founder and CEO of the CATS Foundation, about the world of rare disease advocacy. Dan shares his personal journey as a patient advocate and discusses the mission of the CATS Foundation, which focuses on raising awareness and driving research for Tay-Sachs and Sandhoff disease. He highlights the importance of collaboration and transparency in advocating for better treatment options, emphasising the need for data sharing, especially in drug repurposing efforts. Dan also shares insights into engaging with pharmaceutical companies, emphasising the importance of building trust, clear communication, and collaborative strategies. Throughout the conversation, the critical role of patient voices, diverse perspectives, and community involvement in shaping advocacy efforts is emphasised, ensuring that the needs and experiences of individuals impacted by rare diseases are at the forefront of research and development initiatives. ’s eldest daughter Amelie was diagnosed with Tay-Sachs in 2011 at 15 months of age and upon finding that there was no dedicated advocacy group providing support for families affected by this disease in the UK he set set-up the Cure & Action for Tay-Sachs (CATS) Foundation with his wife Patricia. Since the group was launched, they have been able to grow The CATS Foundation so that it now offers a variety of services to its family members and has been actively involved in the research investigating therapeutic treatments for Tay-Sachs and Sandhoff disease. In addition to this, Dan is the one of the founding members and Chairman of the European Tay-Sachs and Sandhoff Charity Consortium which brings together all the European patient groups leading the fight against the diseases and is part of the team establishing the IGGA, a global organisation bringing together all the advocacy groups for GM1 and GM2. Dan is fully committed to leading the charity towards its goal of finding a treatment so that there is hope for those families affected by Tay-Sachs and Sandhoff in the future Other relevant references | Outras referências relevantes: Contacts | Contactos: Episode edited by
/episode/index/show/cruzamentopodcast/id/30726783
info_outline
79: Cristina Fraga: Desmistificar o Burnout [PT]
03/26/2024
79: Cristina Fraga: Desmistificar o Burnout [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com , CEO da mindout, uma Health Startup focada na saúde mental. Nesta conversa, a Cristina partilha a sua transição do mundo corporativo para o empreendedorismo, discutindo a importância do tema da saúde mental nas empresas e na sociedade. Exploramos o impacto do Burnout, a sua prevalência global e consequências económicas, bem como estratégias para identificar e mitigar esta condição nas organizações. Além disso, abordamos desafios na implementação de programas de prevenção, a importância da liderança na quebra do estigma e como a tecnologia pode ser utilizada para melhorar a saúde mental dos colaboradores, especialmente no contexto do trabalho remoto. Por fim, discutimos a relevância de fornecer suporte e ferramentas para estudantes universitários lidarem com estas questões. é Fundadora e CEO da mindout, uma health/brain-tech startup sediada em Lisboa, que opera na área da saúde mental e está disponível para estudantes universitários, trabalhadores e empresas e profissionais de saúde de todo o mundo. Cristina é Engenheira Informática do IST, trabalhou 8 anos na Deloitte, 2 anos na Deloitte PT e 6 anos na Deloitte US nos escritórios de San Francisco e Manhattan, sempre na área da Tecnologia. Voltou para Portugal em 2013 onde esteve 8 anos na EDP, também ligada ao Digital e Marketing Digital. Em 2020 tirou um Executive MBA no INSEAD e juntou-se à Liberty Insurance como Chief Marketing Officer da Europa. Como sempre teve vontade de criar valor na área da saúde, após a saída de um burnout em 2022, decidiu criar a mindout, utilizando a experiência que viveu nessa mesma jornada, o know-how de business management e liderança com o seu lado tecnológico, para criar uma solução escalável e sustentável para prevenção e reversão de burnouts com uma jornada clara e transparente, com grande foco em Inteligência Artificial. Other relevant references | Outras referências relevantes: Contacts | Contactos: Episódio editado por
/episode/index/show/cruzamentopodcast/id/30516473
info_outline
78: Alan Triggs: Leadership, Longevity and the AI Revolution [EN]
03/12/2024
78: Alan Triggs: Leadership, Longevity and the AI Revolution [EN]
In this episode of Cruzamento Podcast, hosts André Correia and Daniel Guedelha explore the intersections of technology, healthcare, and leadership with , Chief Digital Officer for Nokia. They delve into the impact of AI on industries, discussing the evolution of AI, its role in job creation and displacement, and its potential impact on healthcare and education. Alan shares insights on data management, privacy concerns, and the role of regulation in technology. The discussion extends to the personal experiences, touching on longevity, wellness, and the importance of sleep hygiene in the digital age. Alan also shares experiences from relocating to Portugal and Nokia’s investment in the country. Tune in to explore these topics and more in this insightful episode. is the Chief Digital Officer for Nokia globally, with responsibility for Nokia’s information technology (IT) and digitalisation initiatives. In this role, he is responsible for the global infrastructure for enterprise computing, networking, and end-user services, and enterprise applications covering R&D, services, supply, and financial & commercial systems. He is responsible for number of digital transformation initiatives including a company-wide cloud transformation, the modernisation of core application systems, and the corporate data strategy. Alan has held a number of leadership roles in IT; Telecom and has lived and worked in in seven countries across Africa, Europe and the US. He is currently based out of Portugal. Other relevant references | Outras referências relevantes: Contacts | Contactos: Episode edited by
/episode/index/show/cruzamentopodcast/id/30331868
info_outline
77: Luís Oliveira: Inovações no tratamento da Doença de Parkinson com a The Michael J. Fox Foundation [PT]
11/28/2023
77: Luís Oliveira: Inovações no tratamento da Doença de Parkinson com a The Michael J. Fox Foundation [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha dialogam com , Senior Associate Director Research Programs na The Michael J. Fox Foundation, abordando a missão inspiradora da fundação, o impacto global das doenças neurodegenerativas em saúde e economia, e estratégias eficazes para mitigar riscos na Doença de Parkinson. is a Senior Associate Director of Research Programs at The Michael J. Fox Foundation and the Founder of v-ATPase Alliance for rare diseases due to v-ATPase defects. Luís is an expert in the field of Parkinson’s disease research and investment with more than 15 years of experience in the neurologic diseases space. Currently, he holds the position of Senior Associate Director of Research Programs at The Michael J. Fox Foundation, where he leads various efforts for therapeutic and biomarker development in priority genetic targets in Parkinson’s disease accounting for over $30 million in executed projects. Additionally, Luis Miguel Oliveira is a founder of the v-ATPase Alliance, an organization aimed at connecting families affected by rare diseases related to v-ATPase with the research and medical communities to further advance therapeutic development. With a strong commitment to advance novel treatments from the bench to bedside, Luis Miguel Oliveira serves as a Review Editor for Frontiers in Neurology, Neuroscience and Psychiatry, and as an Investment Advisor for Portugal Ventures, where he leverages his expertise to guide investment decisions in promising ventures. Recently, Luis Miguel Oliveira had an integral contribution to a landmark study that validated the first biomarker for Parkinson’s disease diagnosis. This significant achievement was reported in Lancet Neurology with broader international media coverage and is changing the Parkinson’s research and drug development fields by enabling an objective characterization of the disease based on its biological features. Luis Miguel Oliveira’s educational background includes a degree in Biochemistry from the Faculty of Sciences of Lisbon University. He further pursued his academic journey with a PhD in Molecular Biophysics from the same institution. During his postdoctoral research experience, he conducted his studies at renowned institutions such as the Max Planck Institute for Biophysical Chemistry in Germany and Columbia University in New York. Other relevant references | Outras referências relevantes: Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/28787273
info_outline
76: Stefan Buttigieg: Intersecting Cultural Transformation with Healthcare [EN]
11/14/2023
76: Stefan Buttigieg: Intersecting Cultural Transformation with Healthcare [EN]
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with , about the impact of AI on healthcare. Highlights include AI’s potential in public health, data sharing challenges in Europe, AI projects in Malta, and the importance of equity and ethical data handling in healthcare. Dr. is a Specialist in Public Health Medicine working in the Ministry for Health in Malta !🇲🇹 He is a Keynote Speaker with 50+ public speaking engagements track record and an avid content creator!📱🎙️. He is the manager of the National Contact Point of eHealth and lectures at the University of Malta on the topics of Digital Health, Social Media in Healthcare and Digital Therapeutics. He is the Vice-President of the EUPHA Section on Digital Health and is a WFPHA Governing Council Member. Dr Buttigieg is on a mission to enable equitable Digital Health and Health Data for All ensuring that no one is left behind Other relevant references | Outras referências relevantes: Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/28507955
info_outline
75: Ana França & António Gonçalves: Revolutionizing Organ Donation Through Technology [EN]
10/31/2023
75: Ana França & António Gonçalves: Revolutionizing Organ Donation Through Technology [EN]
In today’s CRUZAMENTO Podcast, André Correia and Daniel Guedelha talked with and . They delve into Health, Technology, and Sustainability, with a focus on transplantation, common transplant types and their impact, insights from companies expanding globally, and future trends in transplantation technology. The discussion showcases TransplantHUB’s role in harnessing these advancements for patient benefit. Meet , a highly skilled and dedicated organ donation and transplantation management expert. With over a decade of experience, Ana has been instrumental in transforming Portugal’s organ donation and transplantation system, improving patient outcomes, and increasing access to life-saving procedures for those in need. Her global initiatives in developing digital transplantation registries have revolutionized how organ donation and transplantation procedures are managed worldwide, earning her recognition as a leader in her field. Ana’s expertise in organ donation and transplantation and her passion for improving patient outcomes make her an invaluable asset to managing organ donation and transplantation. With over 25 years of experience in IT Services, brings together a vast experience in business analysis with a comprehensive technical area know-how in diverse industries, including Healthcare, Insurance, Local Government, Industry, and Logistics. This experience, and above all, the unquestionable ability to apply it in various sectors, allowed him not only to create reasonable conceptual solutions but, above all, practical solutions amenable to a linear technical implementation. His adaptability to a diverse audience, both functional and technical, has allowed him to design innovative products and, more importantly, create practical, innovative solutions with a linear technical implementation. Other relevant references | Outras referências relevantes: Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/28459274
info_outline
74: Patrícia Calado: Qual a estratégia para o futuro da investigação? [PT]
10/16/2023
74: Patrícia Calado: Qual a estratégia para o futuro da investigação? [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com sobre estratégias de inovação e pesquisa na saúde, bem como a necessidade de avaliar adequadamente os investimentos públicos nesta área. A interdisciplinaridade na pesquisa médica é também destacada como crucial para solucionar problemas complexos de saúde. is a results-driven professional dedicated to accelerating positive impact through the uptake of innovation into healthcare. Her career was built on collaborative work with healthcare institutions, industry, and research organizations all over the country. Currently she’s a member of the Board at NOVA Medical School (NMS), as Vice-Dean for Research, and she’s responsible for developing and implementing the faculty’s research and innovation strategy, in close articulation to the Dean. Previously she worked for different innovation and funding agencies in Portugal as the National Contact Point and Delegate for Health in the EU Research and Innovation Programme (2015–2022). Between 2020 and 2022 she was a member of the Board at the Agency for Clinical Research and Biomedical Innovation (AICIB), were she led the international strategy of the Agency and set up the team of National Contact Points and Delegates for Health. She has 25+ years of experience in the fields of Health and Life Sciences with experience in the coordination of multi-disciplinary teams in the context of academia, SME, and governmental agencies. She’s driven by inspiring and motivating people to achieve a shared vision and goals. During her career she implemented processes of transformational leadership by encouraging innovation and empowering her teams to take risks and learn from mistakes, while creating a culture of trust, openness, and learning in the organization. She has a PhD in Biomedical Sciences from the Faculty of Medicine of the University of Lisbon and a degree in Biology from the Faculty of Sciences and Technology of the University of Coimbra. Other relevant references | Outras referências relevantes: Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/28319609
info_outline
73: Ron DePinho: Pioneering Cancer Combat with Tech Breakthroughs [EN]
10/02/2023
73: Ron DePinho: Pioneering Cancer Combat with Tech Breakthroughs [EN]
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with who delves into his contributions to cancer research and innovation, emphasizing the transformative potential of biotechnology in this critical field. His work is dedicated to advancing our understanding of cancer biology, enabling the development of more precise diagnostic tools and targeted therapies. Through his efforts, he aims to revolutionize the way we approach cancer treatment, with the ultimate goal of improving patient outcomes and quality of life. Additionally, Ron de Pinho actively engages in educating influential figures such as the President of the United States and the Pope, advocating for policies that support the advancement of biotechnology in healthcare and sustainability. His dedication to both research and advocacy solidifies his position as a leading figure in the biotech industry. is currently past president and distinguished university professor of The University of Texas MD Anderson Cancer Center. His research has focused on the fundamental mechanisms driving cancer and aging and the clinical application of such knowledge to prevent and treat disease. Dr. DePinho studied biology at Fordham University, where he graduated class salutatorian, and received his M.D. degree with distinction in microbiology and immunology from the Albert Einstein College of Medicine. He performed his residency and postdoctoral training at Columbia-Presbyterian Medical Center. Dr. DePinho’s independent career began at Einstein as the Feinberg Senior Faculty Scholar in Cancer Research and an ACS Research Professor. He then joined the Dana-Farber Cancer Institute and Harvard Medical School where he was the founding Director of the Belfer Institute for Applied Cancer Science and a Professor of Medicine and Genetics at Harvard. As president of MD Anderson, Dr. DePinho conceived and launched the Moon Shots Program, a goal-oriented comprehensive effort designed to accelerate declines in cancer incidence and mortality. This initiative has yielded practice-changing advances in cancer and inspired the national cancer moonshot under President Biden. He also elevated MD Anderson’s research and graduate programs, recruited many world class faculty including National Academy Members and its first Nobel Prize. To improve cancer care beyond MD Anderson, he launched and assembled a network of cancer institutions in 24 countries, reaching one-third of the human population. As a researcher, he has published over 400 articles, books and chapters that have advanced our understanding of cancer, aging and degenerative disorders which have led to clinical advances including new cancer drugs and diagnostics. His most notable discoveries include elucidation of the core molecular pathway for aging, determination of the basis for the intimate link between advancing age and increased epithelial cancer incidence, establishment of the central role of telomeres in cancer genome instability, discovery of Sin3 and linkage of sequence specific transcription factors and chromatin regulators, demonstration that aging itself can be reversed which led to new therapeutic strategies for aging and age-related diseases including Alzheimer’s Disease. To translate these basic discoveries, he founded 9 private and publicly traded biotechnology companies and served as an advisor or director for biotech and large biopharma companies focused on oncology. His public service includes advisory and directorship roles for AACR and the NIH, as well as the Vatican and several countries. He is chairman and co-founder a non-profit, OPA Health (previously, Unite to Prevent Cancer) whose mission is disease prevention in underserved communities. As an advocate, he was a key instigator in the bipartisan bill raising the age of tobacco purchase to 21 (T21) and the bipartisan Cures Act. He is Vice Chair of the BOD for Act For NIH, a non-profit advocacy organization to garner bipartisan support for the NIH resulting in an additional $14.9B to the base budget and restoring the NIH budget following years of inflationary decline. For his fundamental contributions to cancer and aging and to healthcare, he has been recognized with numerous honors and awards. He was named one of the 100 most influential healthcare leaders, according to Modern Healthcare. His honors include the Melini Award for Biomedical Excellence, the American Society for Clinical Investigation Award, the Biomedicum Helsinki Medal, Albert Szent-Györgyi Prize, AACR Clowes Award, American-Italian Foundation Prize, among others. He is a member of the National Academy of Medicine and the National Academy of Science, and a fellow of the American Academy of Arts and Sciences, the American Association of the Advancement of Science and the American Association of Cancer Research. He received Fordham University’s McMahon Memorial Award for Distinguished Public Service, honorary degrees from Harvard University and Hofstra University, and the Ellis Island Medal of Honor. For his work to improve the health of Portugal’s people, Dr. DePinho was recognized by its president with the highest commendation, the Order of Saint James of the Sword. Other relevant references | Outras referências relevantes: Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/28196753
info_outline
72: Katrien Buys: Can Digital Transformation Improve Inclusion & Health? [EN]
09/18/2023
72: Katrien Buys: Can Digital Transformation Improve Inclusion & Health? [EN]
In today’s CRUZAMENTO Podcast, André Correia e Daniel Guedelha talked with about her experiences in the AXA and Ageas merger, highlighting the challenges faced and the strategies that led to success. She also discussed Impact Investing, a concept that stirs controversy among traditional investors, drawing from her role at the Ageas Foundation. Katrien’s inspiring take on Innovation and the Role of Failure underscores how failures can drive progress, backed by compelling examples. This interview offers a profound exploration of these crucial topics that resonate universally. was born and raised in Belgium, and a mathematician by education at the Catholic University of Leuven (KU Leuven Belgium). This degree led her to start in the insurance industry where she worked in the Belgian entity of the group during several years. Triggered by a need of exploring the business world beyond its boundaries, a guiding principle that she keeps valid until today, she set off in 2012 to join the Italian operations and have her first international working experience. After a return to Belgium for 2 years, leading a strategic transformation program, she took the bigger opportunity of travelling and moving with her family to Portugal. Katrien bridges the gap between her work at Ageas Portugal and impact organizations, creating new business opportunities for positive societal impact. She likes to be innovative and to always find ways to cooperate in different areas, creating value both for these organizations and for Ageas Portugal. More importantly, she asks questions regularly, most often “why?” which is the most powerful question to keep you on track and ensure you don’t take anything for granted. Because she works in strategy, innovation and sustainability, she sees her role as bringing people together, having good conversations and co-creating a world of hope for as many people as possible. In the spirit of Ageas Portugal’s mission to deliver emotional and meaningful experiences in people’s lives, there is the vision that, with radical collaboration, we can be a welcome presence in every Portuguese household. Katrien is the winner of the 2021 MAZE Runner Award. Other relevant references | Outras referências relevantes: Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/28055616
info_outline
71: Carlos Oliveira: Qual o impacto das Fundações no ecossistema? [PT]
09/04/2023
71: Carlos Oliveira: Qual o impacto das Fundações no ecossistema? [PT]
Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com que partilha a sua opinião sobre o papel das fundações no ecossistema da Saúde e Tecnologia em Portugal, e como podem ajudar a impulsionar o desenvolvimento destes setores. Falámos também sobre o foco que Braga coloca nas áreas da Tecnologia e Saúde e, os principais resultados alcançados. é cofundador e Presidente Executivo da Fundação José Neves. Com um percurso ligado à economia, à inovação e ao empreendedorismo, ocupou o cargo de Secretário de Estado do Empreendedorismo, Competitividade e Inovação, no XIX Governo Constitucional. Foi também conselheiro do Conselho Europeu de Inovação (EIC), entre 2016 e 2021, sendo o único representante português. Criou aos 22 anos, a sua primeira empresa, a MobiComp, que seria adquirida pela Microsoft em 2008. É um empreendedor em série, tendo co-fundado e investido em diversas startups como a Automaise, iMobileMagic, Asap54, PeekMed, Cardmobili, entre outras. Foi condecorado pelo Presidente da República Jorge Sampaio como Oficial da Ordem de Mérito. Other relevant references | Outras referências relevantes: Contacts | Contactos:
/episode/index/show/cruzamentopodcast/id/27926787